Next Generation Sequencing (NGS, deep sequencing) is revolutionizing the use of sequence information to understand genomes and genome variability. While NGS has allowed the rapid sequencing of large genomes, it has also allowed the allowed an analysis of the genetic diversity in organisms with small genomes. However, the use of NGS to measure population diversity is fraught with artifacts in when each sequence is considered as an independent observation/genome. The high error rate of the sequencing protocols and misincorporation during PCR amplification introduce artifactual diversity. PCR resampling of the same template sequences after amplification introduces artifactual homogeneity. Neither of these serious problems is addressed in most of the application of NGS to complex populations such as HIV-1. We have developed the Primer ID approach specifically to overcome these problems. In this application we propose to define the strengths and weaknesses of the Primer ID strategy and to use this strategy to explore fundamental features of HIV-1 population structure and evolution. These studies will provide definitive answers to longstanding and important questions that impact the relevance of pre-existing variants prior to drug therapy and the potential pathways for HIV-1 evolution. The experiments will use human samples so that the results will be directly applicable to understanding the nature of virus-host interactions in the context of this pathogenic infection.

Public Health Relevance

Our understanding of a biological system is often limited by the tools available to view that system. Next Generation Sequencing has the potential to provide an unprecedented new look at HIV-1 populations. The size and structure of the population is a major determinant of the biology of the virus in how it evolves. Next Generation Sequencing will give us a greatly improved understanding of the HIV-1 population if it is appropriately applied to the question of sequence diversity.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AI108539-02
Application #
8709990
Study Section
AIDS Molecular and Cellular Biology Study Section (AMCB)
Program Officer
Fitzgibbon, Joseph E
Project Start
2013-08-01
Project End
2015-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
2
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Biochemistry
Type
Schools of Medicine
DUNS #
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599